1.	Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0524, NCT00238420
2.	E7389 in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CCC-PHII-75, 7435, NCI-7435, NCT00365157
3.	Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDX1401-01, NCT00948961
4.	Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: NCI Protocol IDs: MDA-ID-030111, NCT00082706
5.	Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: MUSC-AVF-3312, 100892, MUSC-HR-15537, GENENTECH-AVF-3312, NCT00268450, MUSC-CTO-100892
6.	Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FER-GU-004, NCT00350025
7.	Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCC 2005.145, NCT00393796
8.	Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: NCI Protocol IDs: CINJ-3330, NCT00161187
9.	Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-Naive Patients With Advanced/Metastatic Bladder Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0609001823, NCT00461851
10.	Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2006-0620, NCT00506155
11.	Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCC 2007.061, NCT00585689
12.	Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-006, NCT00588666
13.	Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA182-026, NCT00633789
14.	Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCC 2007.097, NCT00645593
15.	Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: WCCC-UWI06-8-01, UWI06-8-01, CO06810, H2007-0250, 07-1270-03, NCT00666562
16.	Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PDX-011, NCT00722553
17.	Phase II Trial of BIBW 2992 in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification. Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.26, NCT00748709
18.	Neoadjuvant Erlotinib (Tarceva) in Transitional Cell Carcinoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 2007-0704, NCT00749892
19.	Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: MCC-15441, IRB 10718, NCT00751140
20.	Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2007-0933, NCT00756639
21.	Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0712, RTOG 0712, NCT00777491
22.	Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: GRID, NCT00765570
23.	Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-208, NCT00808639
24.	Gemzar, Cisp, Sunitinib Urothelial Ca Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06040, NCT00821327
25.	Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HOG GU07-123, NCT00859339